BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center For Technology Licensing - ECPv6.11.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://ctl.cornell.edu
X-WR-CALDESC:Events for Center For Technology Licensing
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260506T120000
DTEND;TZID=America/New_York:20260506T130000
DTSTAMP:20260407T153026
CREATED:20260315T162222Z
LAST-MODIFIED:20260407T180804Z
UID:10000595-1778068800-1778072400@ctl.cornell.edu
SUMMARY:Lab to Impact: The Hard Reality of Building a Biotech Startup - A CEO's Perspective
DESCRIPTION:What does it take to build a biotechnology company that advances early academic assets into a therapy used at the bedside\, while overcoming the scientific\, clinical\, and financial hurdles along the way? \nIn this session\, Laurence Blumberg\, MD\, MBA\, a physician and serial biotech entrepreneur\, shares a candid perspective drawn from decades of experience founding biotechnology companies and advancing scientific discoveries into clinical development. As founding CEO of Syntimmune\, he guided the company through early clinical development before its acquisition by Alexion in 2018 for up to $1.2 billion. Earlier\, he co-founded Syntonix Pharmaceuticals\, where his early strategic vision helped shape a protein engineering platform later acquired by Biogen in 2007. That platform ultimately enabled the development of Eloctate and Alprolix\, long-acting therapies for hemophilia A and B that have significantly improved care for patients with bleeding disorders. \nThis conversation examines the operational and strategic realities of building a therapeutics company. Topics will include: \n\nUnderstanding the structure of the biotechnology ecosystem\nDeveloping a rigorous Target Product Profile and market thesis\nDeciding when to build internal capabilities versus leveraging external partners such as CROs and CDMOs\nSecuring the capital and strategic partnerships required to advance therapies through development\n\nResearchers\, physicians\, and aspiring bioentrepreneurs are invited to join this candid conversation. \nHosted by Lynda Inseque\, director of Technology & Venture Initiatives and Engagement at CTL. \nRegister here. 
URL:https://ctl.cornell.edu/event/lab-to-impact-the-hard-reality-of-building-a-biotech-startup-a-ceos-perspective
CATEGORIES:CTL Events
ATTACH;FMTTYPE=image/png:https://ctl.cornell.edu/wp-content/uploads/2024/09/CTL_CommVenture_icon2-e1770768070564.png
LOCATION:https://ctl.cornell.edu/event/lab-to-impact-the-hard-reality-of-building-a-biotech-startup-a-ceos-perspective
END:VEVENT
END:VCALENDAR